Guy Kyra, Arinaitwe Jim, Goma Fastone Mathew, Atuyambe Lynn, Guwatudde David, Zyambo Cosmas, Kusolo Ronald, Mukupa Musawa, Musasizi Ezekiel, Wipfli Heather
University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Makerere University School of Public Health, Kampala, Uganda.
BMJ Open. 2025 Mar 12;15(3):e090817. doi: 10.1136/bmjopen-2024-090817.
Extended life expectancy due to treatment improvements has increased the diagnosis of cancer among people living with HIV (PLWH) in Africa. Despite documented impacts of stigma on cancer preventive behaviours and care, little is known about the intersections of cancer and HIV stigma and the effects on prevention and care behaviours for both conditions. This study aims to examine experiences and drivers of cancer stigma and their associations with access to and utilisation of cancer prevention services among PLWH.
This was a qualitative study consisting of eight focus group discussions with PLWH and 14 key informant interviews with HIV healthcare providers collected in January 2024.
Data were collected from two districts of Uganda and Zambia. In Uganda, the two selected districts were Arua, in the northern West Nile region, and Moroto, in the northeast Karamoja region. In Zambia, the study districts were Mongu, in the Western Province, and Chipata in the Eastern Province.
Each study district held two PLWH focus groups (one male, another female) with 5-7 participants per group and 3-4 key informant interviews for a total of 55 participants. PLWH and healthcare providers were eligible if they were (1) aged 18 years or older and (2) an HIV-positive client receiving antiretroviral therapy services at the participating clinic or working in a health services capacity at the clinic.
Cancer stigma drivers included widespread misconceptions about disease origins and outcomes, associations with other stigmatising conditions and behaviours such as HIV, TB, and substance use, limited treatment options that heightened fears of diagnosis and inadequate training of healthcare providers. Study participants noted that experiences of stigma led to reduced treatment-seeking behaviours among PLWH, increased social isolation, and poor cancer-related care practices within clinics. Recommended interventions to combat stigma included improved education for providers and patients, private counselling, and peer support.
Results underscore the presence and impacts of stigma in the study population, emphasising the need for research informing culturally sensitive interventions that enhance educational outreach and promote engagement in care among targeted populations.
This article is linked to an ongoing clinical trial registered on clinical trials.gov (clinical trial No: NCT05487807; Registration date: 27 November 2023) and relates to the pre-results stage.
治疗手段的改进使预期寿命延长,这增加了非洲艾滋病毒感染者(PLWH)中癌症的诊断率。尽管有文献记载耻辱感对癌症预防行为和治疗的影响,但对于癌症耻辱感与艾滋病毒耻辱感的交叉点以及对这两种疾病预防和治疗行为的影响知之甚少。本研究旨在调查癌症耻辱感的经历和驱动因素,以及它们与艾滋病毒感染者获得和利用癌症预防服务之间的关联。
这是一项定性研究,于2024年1月收集了与艾滋病毒感染者进行的八次焦点小组讨论以及与艾滋病毒医疗服务提供者进行的14次关键信息访谈。
数据收集自乌干达和赞比亚的两个地区。在乌干达,选定的两个地区是西尼罗河地区北部的阿鲁阿和东北卡拉莫贾地区的莫罗托。在赞比亚,研究地区是西部省的蒙古和东部省的奇帕塔。
每个研究地区举办了两个艾滋病毒感染者焦点小组(一个男性组,一个女性组),每组有5至7名参与者,并进行3至4次关键信息访谈,共有55名参与者。如果艾滋病毒感染者和医疗服务提供者符合以下条件则有资格参与:(1)年龄在18岁及以上;(2)在参与研究的诊所接受抗逆转录病毒治疗服务的艾滋病毒阳性患者,或在该诊所从事卫生服务工作。
癌症耻辱感的驱动因素包括对疾病起源和结果的普遍误解、与艾滋病毒、结核病和药物使用等其他耻辱性状况和行为的关联、有限的治疗选择加剧了对诊断的恐惧以及医疗服务提供者培训不足。研究参与者指出,耻辱感经历导致艾滋病毒感染者寻求治疗的行为减少、社会隔离增加以及诊所内与癌症相关的护理做法不佳。建议的消除耻辱感干预措施包括加强对医疗服务提供者和患者的教育、提供私人咨询和同伴支持。
研究结果强调了耻辱感在研究人群中的存在及其影响,强调需要开展研究,为具有文化敏感性的干预措施提供信息,以加强教育宣传并促进目标人群参与治疗。
本文与一项正在进行的临床试验相关,该试验已在clinicaltrials.gov上注册(临床试验编号:NCT05487807;注册日期:2023年11月27日),且与结果前阶段相关。